Active Ingredient History

  • Now
Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly. It is a p38 mitogen-activated protein kinase inhibitor.   Wikipedia

  • SMILES: CC(C)(C)Cn1c(N)nc2ccc(nc12)c3[nH]c(nc3c4ccc(F)cc4)C(C)(C)C
  • Mol. Mass: 420.54
  • ALogP: 5.55
  • ChEMBL Molecule:
More Chemistry
ly2228820 | ly-2228820 | ly-22288220 | ralimetinib


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue